Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
19624421
DOI
10.1111/j.1524-4741.2009.00760.x
PII: TBJ760
Knihovny.cz E-resources
- MeSH
- Cesarean Section MeSH
- Abortion, Induced statistics & numerical data MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Pregnancy Complications, Neoplastic diagnosis mortality surgery therapy MeSH
- Breast Neoplasms diagnosis mortality pathology therapy MeSH
- Puerperal Disorders diagnosis mortality pathology therapy MeSH
- Antineoplastic Agents therapeutic use MeSH
- Radiotherapy MeSH
- Receptor, ErbB-2 analysis MeSH
- Receptors, Estrogen analysis MeSH
- Receptors, Progesterone analysis MeSH
- Retrospective Studies MeSH
- Pregnancy MeSH
- Delivery, Obstetric MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Greece MeSH
- Names of Substances
- ERBB2 protein, human MeSH Browser
- Antineoplastic Agents MeSH
- Receptor, ErbB-2 MeSH
- Receptors, Estrogen MeSH
- Receptors, Progesterone MeSH
Pregnancy-associated breast cancer (PABC) is a rare and challenging problem. We sought to describe epidemiology, management and outcome of women in whom breast cancer was diagnosed during pregnancy or within one year after delivery. Thirty-two women with PABC were referred to two European Union oncology centers between 1995 and 2007, 16 during pregnancy and 16 within 1 year after delivery. Data concerning diagnosis, management, delivery and fetal and maternal outcome were recorded. A group of 32 patients (matched controls) presenting with nonpregnancy-associated breast cancer (non-PABC) was matched for age at diagnosis, tumor size and stage to each PABC patient. Differences in outcome between the PABC and non-PABC groups were then assessed. Histological features were similar in both groups, except that estrogen receptor-negative tumors were more common in the PABC group. Three patients received chemotherapy and two others underwent surgery during pregnancy, with no excess toxicity or severe maternal/fetal adverse effects. All children in the PABC group were healthy, except for one exposed to epirubicin in utero and born with rectal atresia. Overall survival was similar in PABC and non-PABC patients (p = 0.449). The subgroup of patients with breast cancer diagnosed within one year after delivery showed a shorter time to relapse than controls or patients with gestational cancer (p = 0.0178). PABC is a special situation, necessitating individualized, multi-disciplinary management. Prognosis is similar for women with nongestational cancer matched for age and stage though poorer outcome postpartum should be further investigated.
References provided by Crossref.org